ArticleTranslational cancer research2026
Expression analyses of fatty acid binding proteins (FABPs) in breast cancer subtypes: implications for immune modulation and clinical outcomes.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fatty acid binding proteins (FABPs) are key regulators of lipid metabolism and are expressed in the stroma of breast cancer. However, their roles in different breast cancer subtypes remain unclear. This study explored the expression patterns of FABPs across breast cancer subtypes and examined their associations with immune cell infiltration and clinical features using large datasets, with validation performed through testing in breast cancer cell lines and human tissue samples. Methods: A comprehensive bioinformatic analysis was performed using The Cancer Genome Atlas (TCGA) and Genomic Spatial Event database (GSE) datasets to investigate FABPs' expression patterns and prognostic significance in breast cancer. Prognostic outcomes were evaluated with Kaplan-Meier analysis via PROGgeneV2, and clinicopathological associations, including estrogen receptor (ER)/progesterone receptor (PR) status and tumor grades, were examined using Breast Cancer Gene-Expression Miner v5.1. Immune cell infiltration correlations were assessed through TIMER2.0. Experimental validation was performed by quantitative real-time polymerase chain reaction (qRT-PCR) in breast cancer cell lines (MCF7 and MDA-MB-231) and the non-malignant breast epithelial cell line MCF10A. Independent validation was further conducted in a cohort of frozen breast cancer tissues (n=38). Results: FABPs exhibited distinct expression patterns across breast cancer subtypes. FABP4 was associated with the luminal A subtype and ER-positive status, FABP5 and FABP7 with the basal subtype and ER-negative status, and FABP6 with the human epidermal growth factor receptor 2 (HER2)-enriched subtype. Functional analyses suggested their involvement in immune modulation and other biological processes. FABP expression correlated significantly with immune cell infiltration, particularly CD8 Conclusions: This study identified distinct expression patterns of FABPs across breast cancer subtypes and highlighted their potential roles in immune modulation. These findings offer new insights into the diverse functions of FABPs in breast cancer and their implications for prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.